CU
Clarity Pharma
CU6.AX·ASXSydney AUFounded 2018100 employees
Small CapbiotechPublicOncology
Platform: Cu-64 SARTATE
Market Cap
$1B
All Drugs
2
Clinical Trials
3
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (CU6.AX)
Loading CU6.AX stock data...
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Datofotisoran | CU6-3538 | Phase 1/2 | 2 | C5 | Urothelial CaDMD | ||
| Teranesiran | CU6-6241 | Phase 2 | 1 | IL-17A | Wet AMD |
SEC Filings & Financial Documents
SEC filings are not available for ASX-listed companies.
Clarity Pharma trades on ASX (AU). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (2)